SGLT2 inhibitors → CD4 — Novel Hypothesis | InTree.AI

Novel Hypothesis

SGLT2 inhibitorsCD4

SGLT2 inhibitors enhance CD4+ T cell-mediated regulatory T cell differentiation and function

Convergence: 39%1 bridgeimmunology

Bridge Entities

FOXP3A→B quality: 0.70B→C quality: 0.70

SGLT2 inhibitors PARTICIPATES IN FOXP3, which CONNECTED TO CD4

A→B Evidence (13 total)

“CD4⁺CD25⁺Foxp3⁺ regulatory T cells (Tregs) are potent inhibitors of inflammation and autoimmune diseases.”— CD4⁺CD25⁺Foxp3⁺ regulatory T cells suppress cardiac fibrosis in the hypertensive heart. (2011)DOI

“regulatory T (TReg) cells has focused on the CD4+FOXP3+ TReg cell population.”— Regulatory T cells: CD8+ TReg cells join the fold. (2010)DOI

Why This Is Novel

9 papers mention both entities, but the specific connection through FOXP3 is underexplored — most co-mentions are incidental, not mechanistic.

Discovered by InTree.AI — analyzing 250M+ scientific papers

Bridge Entities

Why This Is Novel

Under Maintenance

Bridge Entities

Why This Is Novel